A children’s health foundation has launched a new financial vehicle to make program related investment in commercial companies developing technologies that can improve children’s health. The foundation expects to make 2-3 equity allocations in the current year. Typical investments range from $150,000 – $250,000 in pre-Series A rounds.  The foundation is seeking opportunities globally.

The foundation funds early stage projects to help them reach scale and sustainability. The foundation is looking for high impact innovations in children’s health with a special interest in neonatal care and pediatric neurology. The foundation is agnostic to technology sectors. The foundation is interested in single assets as well as platform technology that can be applied to the pediatric field.

The foundation seeks privately held companies with competent management teams with sector expertise. The foundation typically seeks board representation post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices throughout the US focuses on several verticals including medical devices, and diagnostics. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm’s target investment size is $1-3M for each portfolio company spread over 1-3 rounds. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

In the life sciences, the firm is currently seeking to invest in early stage research tools, diagnostics, and medical devices. The firm is generally opportunistic in terms of subsectors and indications. The firm will consider products as early as in proof of concept stage, but typically looks at technology 12-18 months from attaining revenue. The company must have solid patent protection.

The firm seeks a strong and experienced management team that has a track record of bringing concept to market, and may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital firm based in California held a first close of a new fund in late 2015 of $75M, and expects to be fully closed in 2016 at $150M. The fund’s investment strategy is somewhat flexible, but seeks to initially invest in series A rounds in the range of $2M-$3M then provide capital throughout the company’s life via additional investments. The firm may write smaller checks (in the range of $250K) to companies that are of very high interest to the fund, but are deemed as too early, to serve as a placeholder for subsequent financing rounds. In terms of capital structure, the firm prefers to participate in priced equity rounds, however convertible notes or other structures may be considered in certain cases. The firm will act as a lead or follow-on investor depending on the nature/terms of the deal and other investors participating in the round.

The firm is most interested in disruptive technologies that target extreme inefficiencies in the healthcare system, such as digital health solutions based on artificial intelligence or big data platforms, as well as cutting-edge technologies and applications in the field of synthetic biology, or other technologies taking elements of data science to improve molecular processes. The firm is not interested in traditional medical devices and diagnostics, but rather devices whose core IP lies within in the backend or software component of the technology.

The firm is open to companies globally, but prefers to invest in companies based on the West Coast. Typically, companies that aren’t located in the U.S. would need to have some operations based in the United States. A lot of emphasis is placed on the strength of the management team when making an investment decision, and the firm seeks to work with entrepreneurs who have a strong understanding of their market and sound logic behind why their vision and business model will be successful. Although successful, repeat entrepreneurs are highly valued, the firm will work with entrepreneurs of all experience levels. Board seats are not required along with an investment, but may be sought depending on the deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharmaceutical company that specializes in Liver Disease, CNS, and Diabetes is actively searching for promising therapeutic candidates under development around the world to invest in or incorporate into its pipeline. The firm is flexible in terms of the structure, and has the ability to invest, in-license, acquire, and co-develop products. If investing in a company, the firm is most interested in private companies, though does look at public companies. The firm will invest in Series A/B companies or assets, and will typically invest between $1M-$5M per allocation depending on the opportunity. The firm is interested in world wide/major territories such as the US, EU, APAC, and East Asia.

The firm is currently seeking promising therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is most interested in therapies targeting liver disease, though is indication agnostic with added interest in neurology, hepatology, oncology, and gastroenterology. The firm is also interested in other therapeutic areas that address unmet medical needs, including orphan disease. The firm will look at both small molecules and biologics and will consider both NCE or NCE-like molecules, as well as re-positioning molecule to a new indication. The firm is not in OTC drugs. The company prefers assets in phase I, II, IND-ready, or preclinical with some in-vivo data. However, the company will also look at assets in phase III and NDA stage.

The firm will consider partnership opportunities from around the world and has no specific management team or distribution right requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A cross-border venture capital fund is currently investing from its roughly $70 million fund closed in 2014. The initial investment size is highly variable although the firm is looking to provide up to $10+ million over the lifetime of the investment. The firm generally provides capital in the form of equity although they also have experience in working with convertible notes. The firm is interested in companies located in North America or Asia, with a special interest in regions outside of traditional biotech hubs. The firm’s primary focus is on private companies while public investments are also made selectively.

The firm is currently interested in companies developing Therapeutics, Diagnostics, Medical Devices, and R&D Services Companies. The firm is entirely opportunistic in terms of subsector and indication. In terms of phase of development, the firm is looking for companies with lead assets in the preclinical stage to companies that already have products on the market. The firm will consider companies in various stages on a case by case basis including seed financing.

The firm views the management team as one of the most important variables in selecting a potential investment. The firm looks for highly experienced and trustworthy management teams. The firm is highly interest in US based companies that are looking to expand into Asian markets or vice versa as member of the fund can add much value in these situations with their vast Asian network. However this US-Asia business development angle is not a criteria or requirement for the firm’s investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that was established in 2000 and is based in the central US is currently in the process of raising its 2nd fund targeted at $50 million. The firm typically makes equity co-investments in seed and early stage companies ranging from $50,000 to $8 million with most investments in the $250,000 to $1.5 million range. The firm makes as many as 12 allocations per year and is open to opportunities throughout the United States and Canada.

The firm is looking for companies in Sectors of Telemedicine, Healthcare IT, Pathology, Diagnostics, Bioinformatics, Medical Devices and more recently Vaccines. The firm does not look at pharmaceutical opportunities. The firm is interested in early stage companies from pre-prototype or pre-clinical to clinical stage that have a cost efficient and innovative product with a clear pathway to exit in approximately 3-5 years. The firm is open to consider all indications and types of devices. The firm is not interested in late stage investments into companies that already have a product on the market. The firm focuses on opportunities that focus on patient care improvements, healthcare IT or products that solve critical problems that hospitals, doctors or patients face—and for which the company can receive reimbursement.

The firm is looking for entrepreneur-based management teams with experience who are open to working with them. The firm looks to take a board seat following investment. In addition to capital the firm is capable of providing strategic mentoring as well as incubation services both locally and remotely in areas of HR, Marketing, Accounting and Software Development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A growth stage venture firm backed by a sole investor manages a portfolio of companies that spans across a variety of industries; about a third of the portfolio is in the healthcare medtech space. The firm has a specific competitive advantage as a long lifetime fund with the ability to invest throughout the lifetime of a company. The firm currently manages a $540M fund and typically invests in series A/B/C rounds with a preference towards series B/C technology at the growth equity stage. The firm typically invests globally at $10M-$30M per company.

The firm has particular interest in innovative products that can apply to other sectors. The firm has particular interest in medical technology—including biodiscovery platforms, next-generation surgical treatments and devices, biomaterials, dental devices, imaging, and regenerative medicine—though is sector agnostic. The firm is also open to therapeutic and diagnostic technology with innovative pathways, as well as both 510K and PMA devices with clear regulatory pathways (FDA approval/benchmarks). The firm typically invests in preclinical/in development technology, though is open to technology in all phases of development. The firm is indication agnostic and has particular interest in pursuing innovative technology in areas where there is not a lot of trending interest with the ability to be the first in the market.

The firm prefers companies with considerable insight and experience in the space. The firm highlights strong, animated founders with transformational vision and technology that have the potential to produce significant revenue traction. The firm supports what is best for the company, whether it be taking a board seat after an investment or helping fill the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com